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targets and eliminates the newly
dominant karyotype.
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Aneuploid genomes, characterized by unbalanced
chromosome stoichiometry (karyotype), are associ-
ated with cancer malignancy and drug resistance of
pathogenic fungi. The phenotypic diversity resulting
from karyotypic diversity endows the cell population
with superior adaptability. We show here, using a
combination of experimental data and a general sto-
chastic model, that the degree of phenotypic varia-
tion, thus evolvability, escalates with the degree of
overall growth suppression. Such scaling likely ex-
plains the challenge of treating aneuploidy diseases
with a single stress-inducing agent. Instead, we
propose the design of an ‘‘evolutionary trap’’ (ET) tar-
geting both karyotypic diversity and fitness. This
strategy entails a selective condition ‘‘channeling’’
a karyotypically divergent population into one with
a predominant and predictably drugable karyotypic
feature. We provide a proof-of-principle case in
budding yeast and demonstrate the potential effi-
cacy of this strategy toward aneuploidy-based azole
resistance inCandida albicans. By analyzing existing
pharmacogenomics data, we propose the potential
design of an ET against glioblastoma.INTRODUCTION
Germline evolution shapes the organismal tree in changing envi-
ronments during the long course of natural history, whereas
acute environmental fluctuation drives asexual cellular evolution,
often associated with dynamic structural changes in the ge-
nomes of microbes or cancer cells (Lewontin, 1970; Merlo
et al., 2006). Aneuploidy (chromosome copy-number imbalance)
is a type of genome alteration widely observed during cellular
evolution of eukaryotic species, such as laboratory (Chen
et al., 2012a; Hughes et al., 2000; Rancati et al., 2008), industrial
(Borneman et al., 2011; Chen et al., 2012b; Infante et al., 2003;Kvitek et al., 2008), and pathogenic (Marichal et al., 1997; Ni
et al., 2013; Selmecki et al., 2006; Sionov et al., 2010) yeasts,
as well as protozoan parasites such as leishmania (Leprohon
et al., 2009; Mannaert et al., 2012; Ubeda et al., 2008) and try-
panosomes (Llewellyn et al., 2011; Minning et al., 2011).
Emerging evidence also points to aneuploidy as an important
driver for the evolution of human cancer (Davoli et al., 2013;
Holland and Cleveland, 2009; Jones et al., 2010; Ng et al.,
2010; Wang et al., 2014). Due to its impact on the expression
of many genes, aneuploidy brings about large phenotypic
changes that can be either detrimental or beneficial in a karyo-
type- and environmental condition-dependent manner (Chen
et al., 2012b; Pavelka et al., 2010).
Aneuploid populations are often characterized by heterogene-
ity—the coexistence of many different karyotypes. The genetic
diversity provides the raw material for evolutionary selection
and endows the aneuploid population with high adaptive poten-
tial (Burrell et al., 2013; Chen et al., 2012a; Maley et al., 2006).
This underscores the exceptional challenge of treating dis-
ease-causing cell populations characterized by large karyotype
heterogeneity and instability (Gerlinger et al., 2012; Harrison
et al., 2014; Lee et al., 2011; Navin et al., 2011; Sotillo et al.,
2010). One idea is to find drugs strongly exacerbating a common
deficiency of aneuploids irrespective of specific karyotype (Oro-
mendia and Amon, 2014). A study found that among a collection
of disomic yeast strains, many showed prominent growth de-
fects toward agents that perturb proteome homeostasis, such
as hygromycin B (a translation inhibitor) or geldanamycin (an
Hsp90 inhibitor) (Torres et al., 2007), supporting the notion that
a common deficiency of aneuploidy is overloading of the prote-
ome quality-control system. However, some of the disomic
strains exhibited resistance, as opposed to sensitivity, toward
proteotoxic agents, and one of the karyotypic features,
increased copy number of chromosome XV (chrXV), emerged
as the adaptive variant when a diploid strain was evolved in
the presence of an Hsp90 inhibitor (Chen et al., 2012a). In addi-
tion, when a highly heterogeneous aneuploid population was
treated with drugs that imposed strong immediate growth inhibi-
tion, long-term culturing enabled evolutionary selection for a few
variants that eventually rendered the population drug resistant
(Chen et al., 2012a) (also see results of this study). These findingsCell 160, 771–784, February 12, 2015 ª2015 Elsevier Inc. 771
highlight the fallacy of short-term efficacy in drug treatments
when dealing with heterogeneous populations already poised
for rapid adaptation.
In this study, we aim for an innovative approach that accounts
for the evolutionary dynamics and achieves long-term growth
suppression or extinction of aneuploid cell populations consist-
ing of a wide spectrum of karyotypes. Our analyses demonstrate
on a general level that the evolutionary potential of a heteroge-
neous aneuploid population escalates under increasing stress,
but such a population may become highly targetable once the
karyotype diversity is drastically confined. These findings led
us to design a two-component strategy for treating diseases
associated with aneuploid cell populations that targets the pop-
ulation’s adaptability and fitness.
RESULTS
Phenotypic Variation Scales with Growth Suppression
under Diverse Stress Conditions in Budding Yeast
To investigate whether certain stress conditions may be consis-
tently effective toward aneuploids with a wide-spectrum of kar-
yotypes, we performed a re-analysis of the growth data from a
previous study subjecting a panel of 38 aneuploid yeast strains
(S. cerevisiae) with diverse and random chromosome stoichiom-
etry to phenotypic profiling across a wide range of conditions
with varying stress types and levels (Pavelka et al., 2010) (Fig-
ure 1A). This analysis revealed a surprising trend: those condi-
tions more toxic to the aneuploidy cohort (lower mean growth
ratio) also produced a larger fitness spread among the aneu-
ploids, such that even under highly toxic conditions, although
many aneuploids failed to grow, some aneuploids endured or
thrived. The standard deviation (spread) and mean of the growth
ratio (overall growth suppression) of diverse aneuploids are
strongly correlated across diverse stress conditions (Figure 1B).
This same trend could also be observed with the set of disomic
aneuploid strains isolated in a previous study (Torres et al.,
2007) treated with increasing concentrations of different drugs
(Figure 1C).
We used a stochastic model to investigate the theoretical
generality of the above experimental observation (Figures 1D,
1E, S1A, and S1B; see Extended Experimental Procedures for
a detailed description of assumptions and simulations). Briefly,
we assumed that fitness is governed by N independent path-
ways, reflecting the modular architecture of cellular systems.
We assume that for each individual pathway the distribution of
pathway activity across diverse karyotypes assumes a simple
normal distribution. Under the stress-free condition, the optimal
fitness is reached by the euploid at the peak of the N-dimen-
sional normal distribution (Figure 1D; Extended Experimental
Procedures), whereas aneuploid populations are located at po-
sitions away from the peak, reflecting suboptimal fitness. In the
presence of stress, however, the optimal fitness point moves
away from the euploid position (Figure 1E). The change in the dis-
tance between the position of each karyotype and the optimal
fitness point represents the fitness change caused by stress.
Simulation of this model with varying values of N revealed two
properties of the system remarkably consistent with experi-
mental observations (Figures 1F and 1G). First, under stress con-772 Cell 160, 771–784, February 12, 2015 ª2015 Elsevier Inc.ditions with sufficient magnitude, most aneuploids had lower
fitness than the euploid, yet there was always a fraction of aneu-
ploids that assumed higher fitness than the euploid. Second, the
absolute value of the mean and standard deviation of the relative
fitness satisfied a positive linear correlation across diverse stress
conditions and a range of N values (Figures 1F, 1G, and S1C–
S1F). The fact that such a simple model could qualitatively cap-
ture the experimental data suggests the observed phenomenon
to be a general property of heterogeneous aneuploid popula-
tions irrespective of specific stress applied.
Therapeutic Compounds Elicit Phenotypic
Heterogeneity in Human Tumor Cell Lines
A vast majority of solid tumors are aneuploid: 91.7% of 817 solid
tumor cell lines surveyed by Cancer Cell Line Encyclopedia
(CCLE) have at least 1 chromosome arm-level copy-number
variation, whereas 58.9% have more than 10 (see Extended
Experimental Procedures). Karyotypic heterogeneity has also
been observed within a single tumor (Gerlinger et al., 2012; Navin
et al., 2011). The relapse fueled by adaptive changes in a tumor
remains a major challenge in cancer treatment. A logical exten-
sion of our findings is that, in karyotypically heterogeneous can-
cer cell populations, the treatment suppressing the overall
growth may also escalate tumor cells’ phenotypic heterogeneity
and potentially adaptability. To examine this possibility, we first
investigated a dataset consisting of 54 karyotypically divergent
human breast cancer cell lines and 77 different anticancer drugs
across 10 concentrations (SU2C breast cancer project; Heiser
et al., 2012). As shown in Figures 2A and 2B, in drug doses
that caused prominent (>50%) overall growth suppression, the
spread of growth rates among cell lines treated with most chem-
icals (95%) also increased. A few drugs showed more consis-
tent toxicity, but due to the lack of a normal euploid control, it is
unknown whether this was specific to aneuploid cancer cells.
Examination of the correlation between overall growth suppres-
sion (-mean) and variation (SD of growth rates) found a consis-
tent positive correlation. Simulation of our multi-dimensional
fitness model with varying N values produced a similar correla-
tion pattern (Figures 2C and 2D). Cell lines from other solid
tumors (e.g., central nervous system, skin, and lung; Barretina
et al., 2012) also demonstrated a similar trend (Figure S2).
Although model simulations showed that for a given stress (X),
a group of aneuploids may be selected for superior fitness, they
also predict that if a second stress (Y) is applied to shift the
optimal fitness in the direction opposite from stress X, those
selected aneuploids would fall into the death zone in the
fitness landscape (Figures 3A and 3B). This implies that if a
highly evolvable population with heterogeneous random karyo-
types can be ‘‘channeled’’ toward a certain karyotypic charac-
teristic under a designed selection (stress X), thus drastically
‘‘shrinking’’ the population’s evolvability, a second treatment
(stress Y) may be added to eradicate the selected singular or
limited karyotypes. Together these two treatments would form
an ‘‘evolutionary trap’’ (ET) on the elusive aneuploid population.
Supporting this idea, for a given specific aneuploid yeast strain,
in most cases one or multiple conditions could be found that
caused >80% growth inhibition compared to the euploid control
(Figure S1G).
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Figure 1. Scaling of Phenotypic Variation
with Growth Suppression in Aneuploids un-
der Diverse Stress Conditions
(A) The growth of 38 aneuploid strains relative to
the euploid, as log2 ratio of aneuploid growth (OD
increase) over the euploid with the nearest ploidy
(see Extended Experimental Procedures), is bin-
ned by growth conditions. Each point in a boxplot
represents an aneuploid strain. The half-length of
each box represents the SD of relative growth
among aneuploids (s), and the middle line repre-
sents the average (m). Note that the horizontal
dashed line across 0 represents the euploid
control.
(B) Phenotypic variation among the aneuploids,
measured as SD of relative growth (s), scales with
average growth defect of the aneuploid cohort
across diverse stress conditions (m).
(C) The growth of 12 disomy strains relative to the
haploid control under increasing concentrations of
hygromycin B (Hygro), amphotericin B (Amph), or
fluconazole (FL). Boxplot representation is as
described for (A).
(D and E) Schematic representation of the model is
shown for the simple case of N = 2 with axes as
labeled. Deep blue to deep red code for increasing
fitness. (D) Graph represents the stress-free con-
dition, where the euploid that is located at the
center of the activity field (position m) assumes the
highest fitness. (E) Graph represents a stress con-
dition, where the optimal fitness point shifts from
m to mk,l, reflecting the activity change necessary
for adaptation. Consequently, the euploid (located
at point m) no longer holds maximal fitness,
whereas higher fitness is assumed by certain
aneuploids (those occupying redder regions).
(F) Example simulation results of the model for 50
random aneuploids under diverse stress condi-
tions (governed by varying type k and magnitude l)
for a 24 dimension space (N = 24), with relative
growth displayed as the experimental data in (A).
The red line shows average log2 growth ratio from
the simulated aneuploid population. Note the
appearance of adaptive aneuploids under high-
stress conditions (toward the right of the graph).
(G) Simulations of the model with a wide range of
N values demonstrate the positive correlation
between s and m in various numbers of di-
mensions. The simulated correlations are shown
in colored lines, whereas the experimental data
are overlaid in gray.
See also Figure S1.Finding Drugs Forming an ET against Heterogeneous
Aneuploid Budding Yeast
To investigate the validity of ET against heterogeneous aneu-
ploids, we first constructed a yeast population with high-degree
karyotypic diversity by sporulation of a homozygous pentaploid
yeast strain. Twenty-eight viable aneuploid meiotic products
with ploidy above 1.9Nweremixed with isogenic diploid, triploid,
and tetraploid cells to mimic karyotype heterogeneity observed
in pathogenic fungi (Harrison et al., 2014) or human cancers (Mi-
telman et al., 2012). Because most aneuploid karyotypes are un-
stable (St Charles et al., 2010; Pavelka et al., 2010; Zhu et al.,2012), the degree of heterogeneity of this mixed population (het-
erogeneous mix) is expected to be far greater, as confirmed by a
broad DNA content profile that did not show bias toward any
specific chromosome gain or loss (Figure S3). To find a selective
condition for karyotype channeling, we took advantage of the
previous finding that growth in high concentrations of radicicol,
an inhibitor of Hsp90 chaperone, selects for extra chromosome
(chr) XV (Chen et al., 2012a). Treatment of three independent
populations of the heterogeneous mix with 50 mg/ml radicicol
all predictably led to convergent evolution toward chrXV gain
(Figures S3C–S3E). Six individual colonies derived from a cultureCell 160, 771–784, February 12, 2015 ª2015 Elsevier Inc. 773
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Figure 2. Phenotypic Heterogeneity of Human Cancer Cell Lines Positively Correlates with Increasing Growth Suppression by Therapeutic
Compounds
The relationship between phenotypic variation (SD of growth rates) and average growth suppression was examined using published drug-response profiling data
from 54 breast cancer cell lines treated with 77 different potential therapeutic compounds over 10 different concentrations (see Extended Experimental
Procedures).
(A) Histograms showing average growth suppression under different drug concentrations.
(B) The SD of growth rates caused by each drug under the range of concentrations tested are shown as a heatmap. Note that drug concentrations for (A) and (B)
are aligned, showing the general trend of increasing SD with increasing growth suppression. The clustering is based on Euclidean distances.
(legend continued on next page)
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that had grown to saturation in radicicol-containing medium
were found to vary in karyotypes but all shared chrXV gain, con-
firming that radicicol caused a selective sweep in the heteroge-
neous mix (Figure S3F).
We next performed a screen for chemicals particularly effec-
tive against chrXV trisomy and identified hygromycin B, a trans-
lation inhibitor (Singh et al., 1979), as the most potent inhibitor of
chrXV trisomy relative to its effect on the diploid control (Fig-
ure S4). We further confirmed potent growth inhibition by
hygromycin B for all six different karyotypes identified from rad-
icicol-selected cultures sharing chrXV gain (Figure 3C). We note
that even though hygromycin B effectively suppressed the
growth of aneuploids that had gained chrXV, this effect did not
extend to all aneuploids: aneuploid strains with increased chrII
or IX dosage but having a normal dosage of chrXV were associ-
ated with superior resistance to hygromycin B compared to the
euploid control (Figures 3D and 3E). However, strains with com-
binations of chrXV, II, and IX gains were highly sensitive rather
than resistant to hygromycin B (Figure 3E).
We showedpreviously that dosage increase ofSTI1 andPDR5,
two genes present on chrXV, are ‘‘driver mutations’’ underlying
chrXV gain-associated radicicol resistance (Chen et al., 2012a).
However, hygromycinB sensitivitywasunrelated todosagealter-
ations of these two genes (Figures 4A and 4B). To identify genes
on chrXV whose increased copy number could cause hypersen-
sitivity to hygromycin B, we screened each of the 453 genes
located on chrXV with its original promoter and carried on a
low-copy (centromeric) plasmid (Ho et al., 2009) and identified 5
genes (CRS5, RPS15, TRM11, RRP6, SER1) (Figures 4C, S5A,
and S5B). Integration of one copy of each top three hit (CRS5,
RPS15, TRM11) recapitulated up to 50% of the hygromycin B
sensitivity of chrXV trisomy in a diploid background (Figure 4E).
However, the effects of these genes were not additive (data not
shown), suggesting that the hygromycin B sensitivity associated
with chrXV gain is an emergent property of gaining many genes
carriedon this chromosomebeyond the three found in the screen.
Consistent with this notion, deletion of a copy of each of the three
hits (CRS5, RPS15, TRM11) individually did not change hygrom-
ycin hypersensitivity of chrXV trisomy (Figure 4F).
Hygromycin B and other proteotoxic agents were previously
proposed to enhance the protein quality-control deficit due to
increased expression of a large number of genes (Oromendia
et al., 2012; Torres et al., 2007). However, the genes whose
dosage increase gave rise to hygromycin B sensitivity were not
all highly expressed genes compared to the other genes located
on chrXV in either euploid or aneuploid with chrXV gain (p = 0.56
for transcripts, p = 0.43 for proteins, Mann-Whitney U test) (Fig-
ures 4C, 4D, and S5C). RPS15, the only highly expressed gene
among the hits, encodes one of 30 proteins within the small ribo-
somal subunit to which hygromycin B binds (Borovinskaya et al.,
2008), suggesting that a direct gene-specific cause underlies(C) At three concentrations that considerably reduced the overall growth rate (>50
m and s across different growth conditions is examined. The linear regression lin
area). Note similar fitting parameters across different drug doses.
(D) The correlation between SD and average growth suppression is also recapitula
(N) in the range of 48–96. The modeled fitting is shown in colored lines, whereas
See also Figure S2.some of the drug sensitivity. Taken together, different molecular
mechanisms are likely to account for radicicol resistance and hy-
gromycin hypersensitivity of aneuploid strains with chrXV gain.
Evolution Dynamics of Cell Populations under Single-
Drug Treatment versus ET
Even though hygromycin B alone potently suppressed the
growth of the chrXV trisomy strain initially, the treated cell popu-
lation eventually adapted, as indicated by growth takeoff after
50 hr (Figure 5A). Karyotyping of the adapted chrXV trisomy cul-
ture revealed that the population was a mixture of euploid and
aneuploid cells that no longer had chrXV gain, but some now car-
ried an additional copy of chrIX (Figures 5B and 5C), consistent
with the result shown in Figures 3D and 3E. This observation re-
confirmed the requirement for chrXV gain in hygromycin B sensi-
tivity and demonstrated the ability of the population to escape
single-drug treatment by continued karyotype change. As ex-
pected, the condition that selected for chrXV, i.e., 50 mg/ml rad-
icicol, was highly toxic to all those survivors that had become
hygromycin B resistant because they had lost the gained chrXV
(Figures 5D and 3E), supporting the rationale of combinatorial
treatment with both radicicol and hygromycin B.
Indeed, the combination of both drugs led to the extinction of
all three independent cultures first subjected to the radicicol
selection (Figures 5F–5H). The same drug pair was similarly
effective against the heterogeneous aneuploid population (het-
erogeneous mix) when added simultaneously (Figures S6A–
S6E). When the heterogeneous mix was treated with a single
chemical, 10 out of 21 tested chemicals (for example,
0.08 mg/ml menadoine and 100 mg/ml radicicol) imposed stron-
ger growth suppression than 50 mg/ml hygromycin B (Fig-
ure S6C). Hygromycin B also ranked low in suppressing euploid
growth (Figure S6A). Yet, when combined with 50 mg/ml radici-
col, hygromycin B, but not menadoine or radicicol, led to the
extinction of the heterogeneous mix (Figure S6D). Thus, the
opposing selective effects of these two drugs on the channeled
karyotype (chrXV gain) imposed an adaptive dilemma for the het-
erogeneous population, leading to its extinction. A potential
pitfall of this ET drug pair is that the diploid with an additional
copy of STI1 showed an enhanced level of resistance against
50 mg/ml radicicol yet without causing hypersensitivity to
50 mg/ml hygromycin (Figure 4A). Such effects due to potential
single-gene gain could be remedied by increasing the concen-
tration (from 50 to 100 mg/ml) of radicicol (Figures S6F and S6G).
An Azole-Based ET for Human Pathogen Candida
albicans
We tested the possibility of using the ET strategy for more effec-
tive anti-fungal treatment. It was previously shown that a
mechanism for human pathogen Candida albicans to confer
resistance to fluconazole, a first-line medicine treating invasive%decrease compared to no drug control in A), the general correlation between
e (red) is surrounded by 95 percentile confidence fitting intervals (darker gray
ted by simulations of themulti-dimensional model with the number of pathways
the published experimental data are shown in gray.
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candidiasis in immune-compromised patients, is gain of isochro-
mosome 5L (i(5L), which contains two copies of the left arm of
chr5) (Selmecki et al., 2006). This aneuploid feature was also
recapitulated in a laboratory evolution experiment selecting for
fluconazole-resistant C. albicans (Selmecki et al., 2009). Thus,
fluconazole may serve as the ‘‘selection’’ drug, which would be
used in combination with a second drug specifically targeting
i(5L) gain. To this end, we screened a chemical library that con-
tained 1,713 FDA- or other regulatory agency-approved drugs,
580 natural compounds, and 420 other bioactive agents against
an i(5L)-containing C. albicans isolate from a 30-year-old male
who developed fluconazole resistance (Marr et al., 1997; Sel-
mecki et al., 2006). We looked for chemicals that showed
much elevated potency against the i(5L)-containing strain
compared to the euploid control generated by spontaneous
i(5L) loss of the original i(5L)-containing strain (Selmecki et al.,
2008). Such drugs were likely to be missed in previous screens
against euploid C. albicans (Okoli et al., 2009; Spitzer et al.,
2011).
A primary screen found that 100 out of 2,713 compounds (Fig-
ure S7A) caused at least 80% growth suppression to either the
i(5L) strain or the euploid, or both. For this set of compounds,
we then determined the concentration causing 80% growth sup-
pression (IC80). In the presence of 26 or 11 conditions, the i(5L)
strain showed significantly (Z test, p < 0.05) higher (i.e., more
resistant) or lower (more susceptible), respectively, IC80 than
the euploid (Figure 6A). As expected, the i(5L) strain exhibited
increased resistance toward a panel of seven other azole deriv-
atives. By contrast, pyrvinium pamoate (PP), a medication for
pediatric pinworm infection, strongly suppressed the growth of
the i(5L) strain but was ineffective against the euploid even at
high concentrations as high as 80 mM after 48 hr culture on
agar (Figures 6A, 6B, and S7B). Given that euploid and i(5L)-
gained C. albicans could co-exist in patients treated with flucon-
azole (Selmecki et al., 2008), we tested the combinatorial effect
of PP with fluconazole in a 1:1 mixed population of both karyo-
types. At concentrations of PP that suppressed the growth of
the i(5L) strain, the resistance to fluconazole regressed from
over 256 mg/ml back to the same level exhibited by the euploid
without PP (Figures 6C and 6D), supporting the ET rationale for
combinatorial anti-fungal treatment.Figure 3. Design and Experimental Implementation of ET in Budding Y
(A and B) Model simulations predict that cell population adapted to a specific stre
shifts optimal fitness in the direction opposite to X, but not by a second stress in a
simplified 2D example similar to that in Figures 1D and 1E but projected to the p
dimensional fitness space under conditions indicated in (A). Note that only the an
1,000 cells were simulated. Each dot represents the relative fitness of an aneupl
growth value.
(C) Six independent colonies isolated from radicicol-adapted population with ga
until saturation was reached in the fastest growing strain. Histograms show a
replicates.
(D) chrII and chrIX disomy strains generated previously by genetic manipulation
radicicol.
(E) Aneuploid strains generated by random triploid meiotic segregation with indica
B. Boxplots show growth relative to the euploid control with each dot representin
dosage, but other chromosome aneuploidy may also be present in these strains
nearest ploidy. The dashed line represents the average of normalized controls. *
See also Figures S3 and S4.A Potential ET against EGFR-Driven Tumors such as
Glioblastoma
In many human cancers, epidermal growth factor receptor
(EGFR) signaling is amajor contributing factor to aggressive phe-
notypes (Wheeler et al., 2010). The human EGFR gene is located
on the short arm of chr7 (chr7p), and chr7p gain is a prevalent
karyotypic feature across diverse types of human cancers (Ber-
oukhim et al., 2010). In particular, chr7 gain was observed in 80%
of glioblastoma samples collected from The Cancer Genome
Atlas Pilot Project (TCGA) cohort of 219 patients (Bredel et al.,
2009; Network, 2008).Within individual tumors, arm-level (mainly
chr7p) or whole-chromosome gain of chr7p was detected in
nearly all surgical sections examined, suggesting that this event,
unlike other heterogeneous genetic alterations, is an early critical
event in clonal expansion (Sottoriva et al., 2013). In addition to
being a likely product of the selection for EGFR-dependent ma-
lignant transformation or adaptation, chr7p polysomy was also
reported in 80% of tumor samples from lung cancer patients
that acquired resistance to gefitinib or erlotinib, EGFR kinase in-
hibitors (Bean et al., 2007). Thus, in designing an ET against
EGFR signaling-dependent tumors, gefitinib or erlotinib may be
used as the channeling drug that could impose a pharmacolog-
ical selection for chr7p gain beyond the selection during tumor-
igenesis. To find the pairing drug that may be particularly toxic
toward chr7p gain, we analyzed the pharmacogenomics data
(Barretina et al., 2012) by correlating the dosage of chr7p of 29
central nervous system (CNS) tumor cell lines with the response
(IC50) to 23 therapeutic compounds (Figure 7A). This analysis
identified a significant correlation between increased chr7p
dosage and increased sensitivity to irinotecan, a drug that is
FDA approved for treating colon cancer but not yet for glioblas-
toma (Figure 7B). This result suggests that gefitinib or erlotinib
together with irinotecanmay form an ET against EGFR-driven tu-
mors, especially glioblastoma where chr7p is already highly en-
riched even without drug treatment (Figure 7E).
DISCUSSION
The analyses presented above started from an exploration of the
general response of karyotypically heterogeneous cell popula-
tions to diverse stress conditions and proceeded to the designeast
ss (X) through karyotype channeling can be highly targetable by a stress Y that
random direction. (A) Schematic representations of the fitness landscape in a
lane defined by pathway activities. (B) Results of model simulations in a high-
euploids selected by Stress X (the top 5% adaptive ones) are shown. A total of
oid cell compared to the euploid. Death zone was defined as having negative
in of chrXV (as shown in Figure S3F) were grown under indicated conditions
verage amount of growth normalized to euploid and SEM derived from four
(Torres et al., 2007) exhibit resistance to hygromycin B yet are sensitive to
ted karyotypic features were cultured in different concentrations of hygromycin
g an aneuploid strain. Karyotypes are categorized by their states of chrII/IX/XV
. The amount of growth (OD increase) was normalized to the euploid with the
* indicates p < 0.01 according to Mann-Whitney U test.
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(legend continued on next page)
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of a strategy to extinct such cell populations that accounts for
their adaptive potential. Growth profiling of yeast aneuploids
demonstrated that the phenotypic variation resulting from karyo-
type diversity scales directly with the degree of average inhibition
of population growth under diverse stress conditions. Mathe-
matical simulations based upon a few simple assumptions
support the generality of our experimental observation. A more
intuitive understanding of this phenomenon may lie in the highly
pleiotropic nature of aneuploidy. The finding from yeast aneu-
ploids was also recapitulated in human cancer cell lines derived
from highly aneuploid solid tumors: the growth-suppressive
effects of a majority of therapeutic compounds also significantly
correlated with phenotypic heterogeneity in a positive manner.
This correlation predicts that a heterogeneous aneuploid cancer
population may harbor large phenotypic variation under stress,
fueling rapid adaptive evolution. Frequent association between
genetic heterogeneity and poor prognosis has indeed been
observed in cancer clinics (Maley et al., 2006; McGranahan
et al., 2012). Chromosomal instability (CIN) in mice also pro-
motes tumor development (Sotillo et al., 2007; Weaver et al.,
2007), although the extent to which genetic heterogeneity con-
tributes to tumorigenesis in common mouse cancer models
remains to be further explored. Beyond aneuploidy, the wide
spectrum and large number of genetic modifications in a given
cancer genome are likely to augment the pleiotropic effects on
cellular pathways caused by aneuploidy.
Our experimental and theoretical findings argue on a general
level that the difficulty of suppressing karyotypically heteroge-
neous cell populations is rooted in the large adaptive potential
in the presence of severe stress. However, our findings do not
rule out the possible existence of agents with broad inhibitory
effects against aneuploids, especially when the karyotypic
space is limited. The principle of ET in fact capitalizes on this
notion by reducing karyotypic heterogeneity to an exceedingly
narrow space through an evolutionary process. In our proof-
of-principle experiments in budding yeast, this confined karyo-
typic space is simply gain of chrXV, which harbors the ‘‘driver
mutations’’ for radicicol resistance (selection), whereas multi-
ple ‘‘passenger’’ genes on chrXV confer enhanced sensitivity
to hygromycin B, the agent for extinction, when increased in
copy number (Figures 7C and 7D). The complex contribution
of gene dosage to hygromycin B sensitivity and the requirement
for multiple genes to achieve radicicol resistance predicted
that an efficient escape from the ET is not easily attainable
through single-gene mutations or copy-number changes.
Although ET is not presumed to be an omnipotent solution for
cancer or fungal infections, we argue that, by accounting for(C and D) Each of 453 genes located on chrXV was transformed into a diploid
population average in the presence of 35 mg/ml hygromycin B were plotted ag
(Ghaemmaghami et al., 2003) of each tested gene in the euploid S288c backg
(including CRS5 and RPS15). The gray area shows the 95% confidence interval
(E) Growth assays showing that copy-number increases (by genomic integration)
diploid euploid context to reproduce enhanced sensitivity to hygromycin B, but no
shown in (A).
(F) Growth assays showing that single-copy deletion of none of the three genes
hyper-sensitivity.
See also Figure S5.the evolutionary trajectory of a cell population, ETmay substan-
tially reduce the risk of evolved drug resistance and disease
relapse.
The principle of ET is distinct from the idea of targeting a sin-
gle characteristic trait of aneuploids. We note that both drugs
used in the yeast ET, radicicol and hygromycin B, can perturb
proteome homeostasis (Oromendia et al., 2012; Singh et al.,
1979; Taipale et al., 2010; Torres et al., 2007), but the responses
of aneuploids to these drugs are karyotype specific rather than
uniform. The rationale behind the dual drug treatments associ-
ated with ET anticipates evolutionary changes and is thus
fundamentally different from the idea of synthetic lethality (Kae-
lin, 2005; Luo et al., 2009) or the use of dual drugs to target
different aspects of a common defect of aneuploidy (Tang
et al., 2011). ET drugs are not chosen to interfere with redundant
processes but rather collaborate to force and intercept a pre-
dicted evolutionary trajectory of the genome. The same karyo-
type feature is selected by one drug but rejected by the other,
as a result of linkage of two pools of genes, which respond
oppositely to the two different drugs, on the same chromosome
(Figure 7C).
Our experiments withCandida provide a possible ET example
where PP, which selects against the gain of i(5L), could enhance
the efficacy of fluconazole, the prior selection favoring i(5L)
gain. PP is extremely well tolerated in the pediatric population
for gastrointestinal treatment due to the near-zero absorption
rate (Smith et al., 1976). Thus, PP may be used to augment
fluconazole if the developed azole resistance is determined
to be associated with i(5L) gain variants originated from gut
flora.
Our analysis of the cancer pharmacogenomics data suggests
that irinotecan may form an ET with EGFR inhibitors against hu-
man cancers such as glioblastoma. Unlike other tumor types
dependent on EGF signaling, glioblastoma responds poorly to
EGFR inhibitors with the erlotinib response rate at <25% (Taylor
et al., 2012). We envision that treatment with an EGFR inhibitor
may further select for and thus increase the percentage of
chr7-gained cells within the tumor mass. Supporting this idea,
it was reported that EGF limitation selects for chr7 gain in human
neural stem cells (Sareen et al., 2009). By analyzing existing
pharmacogenomics data in brain tumor cell lines, we identified
irinotecan, an FDA-approved chemical that targets topoisomer-
ase 1, as a drug whose potency significantly correlates with chr7
gain. Additional experiments will be required to further confirm
this correlation and test the efficacy of an ET formed with
a combination of gefitinib or erlotinib with irinotecan against
glioblastoma.strain, and Z scores denoting the deviation of growth of each strain from the
ainst mRNA (C), using RNA-seq data, or protein expression abundance (D)
round. Note that protein abundance data were not retrieved for 30% genes
for the linear fitting.
of three genes (CRS5, RPS15, TRM11) on chrXV were individually sufficient in a
t radicicol resistance, contrasting copy-number increase for STI1 and PDR5 as
(CRS5, RPS15, TRM11) alone could rescue chrXV trisomy from hygromycin B
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Figure 5. The Combination of Radicicol and Hygromycin B Extincts Karyotypically Heterogeneous Cell Population
(A–E) ChrXV trisomy was able to escape growth inhibition by hygromycin B through loss of the gained chrXV. (A) The growth (represented by OD reading on a
Tecan reader) of both the euploid control and the trisomy XV strain was monitored in media containing 50 mg/ml hygromycin B. (B) The additional copy of chrXV
was lost in hygromycin B culture but not in YPD culture, as shown by the heatmap of karyotyping result of the final culture. (C) Karyotypes of six single colonies
from the trisomy XV culture in YPD or hygromycin are shown, three of which were re-tested for growth in the presence of hygromycin B (D) or radicicol (E). Note
that radicicol sensitivity was re-established in all three adapted colonies from the trisomy XV culture in hygromycin, whereas isolates from the YPD culture
remained radicicol resistant.
(F–H) Combination of hygromycin B and radicicol effectively eradicates the radicicol-preselected aneuploid population. (F) Growth curves (as OD600measured in
Tecan) of the diploid control strain under conditions as indicated. Note that 50 mg/ml hygromycin B alone had milder growth suppression compared to 100 mg/ml
(legend continued on next page)
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Figure 6. PP Effectively Targets the Flucon-
azole-Resistant Candida Aneuploid
(A) Relative IC80 (80% inhibitory concentration) of
thediploid versus the i(5L)Candidastrain for eachof
the hits of the primary drug screen (Figure S7A). The
error bars reflect themodel-based standard error of
fitting reported by drc package in R programming.
(B) Images of agar plates showing effectiveness of
PP toward i(5L) candida.
(C) Resistance of the diploid, the i(5L), or the
i(5L)+diploid mix population toward fluconazole.
(D) PP at concentrations above 10 mM restored the
sensitivity of the i(5L)+diploidmixpopulation toward
fluconazole in the E-test, in accordance to its sin-
gular form’s activity against the i(5L) strain shown in
(B). Note that even though the initial plating density
was the same, due to the inhibition of the i(5L) cells,
the overall growth was less in (D) compared to (C).
Note thatour euploid strain alsoexhibiteda reduced
susceptibility to fluconazole compared to the clin-
ical E-test standard strain, which may be attributed
to other point mutations (such as the hyperactive
TAC1) within this strain (Selmecki et al., 2006). All
plate images were taken after 48 hr culture.
See also Figure S7.EXPERIMENTAL PROCEDURES
Cell Culture
Budding yeast (strains are listed in Table S1, and plasmids/primers used to
construct these strains are listed in Tables S2 and S3) was cultured using
standard media. C. albicans cells recovered from frozen glycerol stocks
were grown on YPD plates. For bulk liquid culture prior to drug-sensitivity
assays, SC media with additional 80 mg/l uridine were used. RPMI1640 +radicicol. (G) Growth curves of three populations pre-selected independently in the presence of radicicol (F
curves of the same three populations as in (G) under indicated conditions where each drug was combined wi
shows the mean and SEM from three experiments.
See also Figure S6.
Cell 160, 771–784,0.165M MOPS buffer + 0.2% glucose without
bicarbonate (Lonza) was used for 96-well culture
according to the Clinical Laboratory and Stan-
dards Institute (CLSI) standard M27-A3. For
384-well cultures, an additional 2% glucose was
added to accelerate the growth. Agar plates
were prepared using RPMI1640 with MOPS
without bicarbonate powder (US Biological) sup-
plemented with 2% glucose and 1.5% agarose,
following the E-test strip manufacturer’s guideline
(bioMerieux).
Yeast Growth Assays
For continuous OD monitoring (e.g., Figure 3D),
cultures were set up in 96-well plates sealed
with parafilm in a Tecan M200Pro reader with
orbital shaking. OD at wavelength 595 nm
was taken every 15 min and analyzed by using
the Magellan 7 software (Tecan). For cultures
whose OD reading was taken intermittently
every several hours (e.g., Figure 5F), the culture
plates were placed in a non-shaking incubator
within a humid chamber before each reading
after agitation. The OD at wavelength 595 nmwas recorded by using a Tecan M200Pro reader, and the data files were pro-
cessed in R. The growth assays lasted until the fastest growing culture
reached saturation, at which time the last OD readings of all strains were
recorded.
The drug concentrations of hygromycin B and radicicol were adjusted for
different media (e.g., YPD versus SC-ura) and/or the strain background, so
that the wild-type control showed the same growth delay as was observed
for the strain RLY2628 in YPDmedia containing the stated drug concentration.igure S3E) under indicated conditions. (H) Growth
th 50 mg/ml radicicol. Each data point in (G) and (H)
February 12, 2015 ª2015 Elsevier Inc. 781
AC
D
E
B Figure 7. A Potential Drug Targeting chr7
Gain in Brain Cancer and Schematic Sum-
mary of the Mechanism and Principle of ET
using the Yeast Example
(A) Correlation coefficients of drug response (IC50)
with chr7p dosage in 29 CNS tumor cell lines
across 23 different therapeutic compounds were
plotted as bar graphs.
(B) The dot plot illustrates the details of the cor-
relation between dosage of chr7p and sensitivity to
irinotecan, with each dot showing the drug
response and chr7p dosage of each cell line. The
red line shows linear fitting, and the gray area
shows the fitting range with 95% confidence in-
terval. Note that a total of 20 cells lines were
included here, as the IC50 data for nine cell lines
were not available for irinotecan.
(C) The molecular makeup of the ET against
aneuploidy yeast.
(D) Schematic summary of opposing selective
effects of radicicol and hygromycin B on chrXV
gain impose an adaptive dilemma for the yeast
heterogeneous aneuploid population.
(E) An ETmay be established against glioblastoma
by opposing selective effects on chr7p gain.The growth of genetic variants was normalized to the corresponding wild-type
controls.
A comprehensive description of all methods used can be found in Extended
Experimental Procedures.
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